| |
| Device | FoundationOne Liquid CDx |
| Generic Name | Next generation sequencing oncology panel, somatic or germline variant detection system |
| Applicant | Foundation Medicine, Inc. 150 Second St. Cambridge, MA 02141 |
| PMA Number | P200006 |
| Supplement Number | S001 |
| Date Received | 03/23/2021 |
| Decision Date | 02/03/2022 |
| APCB Date | 05/26/2023 |
| Product Code |
PQP |
| Advisory Committee |
Pathology |
| Supplement Type | Normal 180 Day Track No User Fee |
| Supplement Reason | Postapproval Study Protocol |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approval of the clinical protocol entitled Statistical Analysis Plan Expanded Validation Study for the Efficacy of Rucaparib in Ovarian Cancer based on F1L CDx. |